Gubra A/S (GUBRA) - Net Assets
Based on the latest financial reports, Gubra A/S (GUBRA) has net assets worth Dkr1.22 Billion DKK (≈ $190.12 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr2.91 Billion ≈ $455.30 Million USD) and total liabilities (Dkr1.69 Billion ≈ $265.17 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Gubra A/S to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Dkr1.22 Billion |
| % of Total Assets | 41.76% |
| Annual Growth Rate | 47.85% |
| 5-Year Change | 463.15% |
| 10-Year Change | N/A |
| Growth Volatility | 135.24 |
Gubra A/S - Net Assets Trend (2019–2024)
This chart illustrates how Gubra A/S's net assets have evolved over time, based on quarterly financial data. Also explore Gubra A/S balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Gubra A/S (2019–2024)
The table below shows the annual net assets of Gubra A/S from 2019 to 2024. For live valuation and market cap data, see Gubra A/S market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Dkr450.57 Million ≈ $70.50 Million |
-6.06% |
| 2023-12-31 | Dkr479.66 Million ≈ $75.05 Million |
+343.28% |
| 2022-12-31 | Dkr108.21 Million ≈ $16.93 Million |
-28.56% |
| 2021-12-31 | Dkr151.46 Million ≈ $23.70 Million |
+89.31% |
| 2020-12-31 | Dkr80.01 Million ≈ $12.52 Million |
+25.55% |
| 2019-12-31 | Dkr63.73 Million ≈ $9.97 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Gubra A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 582.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Dkr434.22 Million | 96.37% |
| Common Stock | Dkr16.35 Million | 3.63% |
| Total Equity | Dkr450.57 Million | 100.00% |
Gubra A/S Competitors by Market Cap
The table below lists competitors of Gubra A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
UEM Sunrise Bhd
KLSE:5148
|
$844.56 Million |
|
Omnijoi Media Corp
SHE:300528
|
$844.58 Million |
|
Indian Metals & Ferro Alloys Limited
NSE:IMFA
|
$844.84 Million |
|
PARATUS ENERGY SERVICES LTD
OL:PLSV
|
$845.09 Million |
|
R&S GROUP HOLDING AG
SW:RSGN
|
$844.27 Million |
|
Sats ASA
OL:SATS
|
$843.77 Million |
|
Fujian MinDong Electric Power Co Ltd
SHE:000993
|
$843.69 Million |
|
Drägerwerk AG & Co. KGaA
XETRA:DRW8
|
$843.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gubra A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 479,659,000 to 450,573,000, a change of -29,086,000 (-6.1%).
- Net loss of 36,498,000 reduced equity.
- Dividend payments of 606,000 reduced retained earnings.
- Share repurchases of 606,000 reduced equity.
- Other comprehensive income increased equity by 1,000.
- Other factors increased equity by 8,623,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Dkr-36.50 Million | -8.1% |
| Dividends Paid | Dkr606.00K | -0.13% |
| Share Repurchases | Dkr606.00K | -0.13% |
| Other Comprehensive Income | Dkr1.00K | +0.0% |
| Other Changes | Dkr8.62 Million | +1.91% |
| Total Change | Dkr- | -6.06% |
Book Value vs Market Value Analysis
This analysis compares Gubra A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.95x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 67.34x to 11.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | Dkr4.90 | Dkr330.20 | x |
| 2021-12-31 | Dkr9.28 | Dkr330.20 | x |
| 2022-12-31 | Dkr6.63 | Dkr330.20 | x |
| 2023-12-31 | Dkr31.62 | Dkr330.20 | x |
| 2024-12-31 | Dkr27.64 | Dkr330.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gubra A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13.73%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.36x
- Recent ROE (-8.10%) is below the historical average (9.46%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 15.86% | 7.37% | 0.88x | 2.44x | Dkr4.69 Million |
| 2021 | 44.85% | 26.61% | 0.85x | 1.99x | Dkr52.79 Million |
| 2022 | 3.98% | 2.16% | 0.76x | 2.43x | Dkr-6.51 Million |
| 2023 | -9.28% | -21.72% | 0.33x | 1.30x | Dkr-92.49 Million |
| 2024 | -8.10% | -13.73% | 0.43x | 1.36x | Dkr-81.56 Million |
Industry Comparison
This section compares Gubra A/S's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $4,607,636,000
- Average return on equity (ROE) among peers: -30.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gubra A/S (GUBRA) | Dkr1.22 Billion | 15.86% | 1.39x | $844.37 Million |
| ALK-Abelló A/S (ALK-B) | $3.29 Billion | -4.80% | 0.51x | $8.12 Billion |
| Bavarian Nordic (BAVA) | $62.33 Million | 0.00% | 0.34x | $2.29 Billion |
| Genmab A/S (GMAB) | $19.12 Billion | 24.88% | 0.11x | $17.05 Billion |
| Pharma Equity Group A/S Cl A (PEG) | $36.39 Million | -118.94% | 12.85x | $14.52 Million |
| Zealand Pharma A/S (ZEAL) | $528.47 Million | -51.52% | 0.40x | $3.47 Billion |
About Gubra A/S
Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metab… Read more